Source - SMW
Canaccord Genuity today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and raised its price target to 241p (from 235p).

Related Charts

Shield Therapeutics (STX)

0.00p (0.00%)
delayed 18:15PM